Dr. Andrew P. Mazar has served as Actuate Therapeutics' Chief Operating Officer since June 2022, after serving as an independent consultant to the company from January to June 2022. A translational oncology researcher and entrepreneur with over 30 years of experience spanning academia and industry, he was previously Co-Founder, Chief Scientific Officer and a director of Monopar Therapeutics, Inc. from 2016 to 2022, and is a founder and managing member of Tactic Pharma, LLC, where he co-invented WTX-101/ALXN1840 (acquired by Alexion Pharmaceuticals for more than $800 million in 2018). He was previously a Professor of Pharmacology and Director of the Center for Developmental Therapeutics at Northwestern University's Feinberg School of Medicine, and Chief Scientific Officer at Attenuon, LLC. He is a co-author of roughly 150 peer-reviewed publications and a co-inventor on more than 100 patents. Dr. Mazar earned a B.S. in Chemistry from the University of Wisconsin-Parkside and a Ph.D. in Biochemistry from the University of Illinois College of Medicine, Chicago.